UBS Group’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $488K | Buy |
108,241
+16,727
| +18% | +$75.4K | ﹤0.01% | 4861 |
|
|
2025
Q1 | $425K | Buy |
91,514
+32,115
| +54% | +$149K | ﹤0.01% | 4786 |
|
|
2024
Q4 | $412K | Buy |
59,399
+34,066
| +134% | +$236K | ﹤0.01% | 4825 |
|
|
2024
Q3 | $134K | Buy |
25,333
+2,039
| +9% | +$10.8K | ﹤0.01% | 4971 |
|
|
2024
Q2 | $87.1K | Sell |
23,294
-17,879
| -43% | -$66.9K | ﹤0.01% | 5146 |
|
|
2024
Q1 | $290K | Buy |
41,173
+3,225
| +8% | +$22.7K | ﹤0.01% | 4465 |
|
|
2023
Q4 | $214K | Buy |
37,948
+14,639
| +63% | +$82.7K | ﹤0.01% | 4564 |
|
|
2023
Q3 | $112K | Sell |
23,309
-466
| -2% | -$2.23K | ﹤0.01% | 4654 |
|
|
2023
Q2 | $163K | Buy |
23,775
+13,369
| +128% | +$91.6K | ﹤0.01% | 4583 |
|
|
2023
Q1 | $81.1K | Buy |
10,406
+1,159
| +13% | +$9.03K | ﹤0.01% | 5026 |
|
|
2022
Q4 | $70.4K | Buy |
+9,247
| New | +$70.4K | ﹤0.01% | 5303 |
|
|
2022
Q2 | – | Sell |
-29,408
| Closed | -$412K | – | 9423 |
|
|
2022
Q1 | $412K | Buy |
29,408
+26,148
| +802% | +$366K | ﹤0.01% | 3881 |
|
|
2021
Q4 | $67K | Buy |
+3,260
| New | +$67K | ﹤0.01% | 5570 |
|